CAR-T:

Zhen Sun1, Jianglong Guo1, Mengsi Liu2

  • 1State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

EClinicalMedicine
|January 7, 2026
PubMed
概括

化学抗原受体 (CAR) -T细胞疗法具有显著的风险. 这项研究确定了266个与CAR-T疗法相关的不良事件 (AE),包括高致死的事件,如肺出血和低致死的事件,如细胞因子释放综合征.